Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells.
Ontology highlight
ABSTRACT: Activating mutations in KRAS are the hallmark genetic alterations in pancreatic ductal adenocarcinoma (PDAC) and the key drivers of its initiation and progression. Longstanding efforts to develop novel KRAS inhibitors have been based on the assumption that PDAC cells are addicted to activated KRAS, but this assumption remains controversial. In this study, we analyzed the requirement of endogenous Kras to maintain survival of murine PDAC cells, using an inducible shRNA-based system that enables temporal control of Kras expression. We found that the majority of murine PDAC cells analyzed tolerated acute and sustained Kras silencing by adapting to a reversible cell state characterized by differences in cell morphology, proliferative kinetics, and tumor-initiating capacity. While we obs
SUBMITTER: Chen PY
PROVIDER: S-EPMC5837062 | biostudies-literature | 2018 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA